Stay informed with free updates
Simply sign up to the Pharmaceuticals sector myFT Digest — delivered directly to your inbox.
Presenting the findings of medical studies rarely attracts standing-room-only crowds, but a recent event in Philadelphia did just that. The presentation was on the efficacy of Wegovy, one of the latest weight-loss medications, in reducing the risk of diabetes and preventing death from a heart attack or stroke by 20%.
Driven by the success of Wegovy and its counterpart Ozempic, both classified as “semaglutides,” pharmaceutical companies are experiencing a surge in prescriptions. These drugs are not only being used by obese and diabetic patients but also garnering interest from various other demographics, including Hollywood stars, pre-diabetic patients, and more.
As a result of this pharmaceutical revolution, numerous industries are witnessing disruptions – from companies developing similar drugs to fast food chains and healthcare providers.
The impact reaches beyond the healthcare and pharmaceutical sectors, affecting businesses ranging from consumer staples to healthcare providers, as the market shifts in response to the changing behaviors of patients on weight-loss drugs.
Moreover, the impact on the US healthcare system raises concerns about costs and long-term implications. While the drugs offer promise, they do not solve the core issues driving American obesity, prompting a critical examination of the long-term ramifications.